Background: Young ovarian cancer (OC) patients often experience a synergistic interplay among tumor progression, estrogen deficiency, and depression, which severely compromises prognosis and quality of life. However, a preclinical model that faithfully recapitulates this triad remains lacking. This study aimed to develop and validate a novel mouse model to investigate the interrelationship between ovarian cancer, hypoestrogenic states, and depression.
Methods: An ovarian cancer–related depression (OCRD) model was established by integrating previously validated components of tumor-depression paradigms, including ID-8 ovarian cancer modeling and chronic restraint stress-induced depressive-like behavior. Orthotopic (intraperitoneal) and heterotopic (subcutaneous) tumor models were combined with chronic stress. Estrogen status was manipulated by ovary retention or ovariectomy (OVX), performed either 1 day before tumor implantation to model preexisting estrogen deficiency or 7 days after engraftment to mimic treatment-induced abrupt hormonal loss. Model validity was assessed using behavioral assays (sucrose preference test, tail suspension test, and open field test), neuroendocrine profiling, and longitudinal evaluation of tumor progression.
Results: The model generated by intraperitoneal tumor engraftment, OVX, and chronic stress exhibited pronounced depressive-like behavior, accompanied by marked estrogen depletion and accelerated tumor progression. All mice survived throughout the experimental period, indicating high model stability and reproducibility. This integrated phenotype closely mirrors key clinical features observed in young OC patients undergoing abrupt estrogen deprivation.
Conclusions: The combination of intraperitoneal ovarian cancer modeling, ovariectomy, and chronic stress induction establishes a stable and clinically relevant preclinical model of hypoestrogenic ovarian cancer–related depression, suitable for translational research.
| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.
|
| [2] |
Nakhlband A, Farahzadi R, Saeedi N, Barzegar H, Montazersaheb S, Soofiyani SR. Bidirectional relations between anxiety, depression, and cancer: a review. Curr Drug Targets. 2023; 24(2): 118-130.
|
| [3] |
Cabasag CJ, Fagan PJ, Ferlay J, et al. Ovarian cancer today and tomorrow: a global assessment by world region and human development index using GLOBOCAN 2020. Int J Cancer. 2022; 151(9): 1535-1541.
|
| [4] |
Ghamari D, Dehghanbanadaki H, Khateri S, et al. The prevalence of depression and anxiety in women with ovarian cancer: an updated systematic review and meta-analysis of cross-sectional studies. Asian Pac J Cancer Prev. 2023; 24(10): 3315-3325.
|
| [5] |
Chen X, Du J, Wang X, Wu X. Trends and projections of ovarian cancer incidence in Hong Kong: a population-based study. Acta Obstet Gynecol Scand. 2023; 102(7): 942-949.
|
| [6] |
Zhu Q, Han Y, He Y, et al. Quercetin inhibits neuronal ferroptosis and promotes immune response by targeting lipid metabolism-related gene PTGS2 to alleviate breast cancer-related depression. Phytomedicine. 2024; 130:155560.
|
| [7] |
Lamkin DM, Lutgendorf SK, Lubaroff D, Sood AK, Beltz TG, Johnson AK. Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain Behav Immun. 2011; 25(3): 555-564.
|
| [8] |
Polityńska B, Pokorska O, Wojtukiewicz AM, et al. Is depression the missing link between inflammatory mediators and cancer? Pharmacol Ther. 2022; 240:108293.
|
| [9] |
Grassi L, Caruso R, Riba MB, et al. Anxiety and depression in adult cancer patients: ESMO clinical practice guideline. ESMO Open. 2023; 8(2):101155.
|
| [10] |
Andersen BL, Lacchetti C, Ashing K, et al. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. J Clin Oncol. 2023; 41(18): 3426-3453.
|
| [11] |
Xiaolei H, Fangmin W, Yiying Z, et al. Neuronal TLR4 overexpression in the medial prefrontal cortex is associated with neuroinflammation and depression-like behaviors in ovariectomized rats. Psychoneuroendocrinology. 2025; 180:107558.
|
| [12] |
Ehlin von Kartaschew Å, Lindén Hirschberg A, Gemzell-Danielsson K, Flöter Rådestad A. Psychological quality of life in BRCA1/2-carriers following risk-reducing salpingo-oophorectomy: a preliminary report. Menopause. 2025; 14(2): 42-50.
|
| [13] |
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48.
|
| [14] |
Bortolato B, Hyphantis TN, Valpione S, et al. Depression in cancer: the many biobehavioral pathways driving tumor progression. Cancer Treat Rev. 2017; 52: 58-70.
|
| [15] |
Fu X, Sun J, Wang X, Cui M, Zhang Q. Research Progress on influencing factors and intervention measures of post-traumatic growth in breast cancer patients. Front Public Health. 2022; 10:927370.
|
| [16] |
Joly F, Ahmed-Lecheheb D, Kalbacher E, et al. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study. Ann Oncol. 2019; 30(5): 845-852.
|
| [17] |
Bai Y, Niu L, Song L, et al. Uncovering the effect and mechanism of Jiawei Xiaoyao Wan in treating breast cancer complicated with depression based on network pharmacology and experimental analysis. Phytomedicine. 2024; 128:155427.
|
| [18] |
Nagaraja AS, Dorniak PL, Sadaoui NC, et al. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. 2016; 35(18): 2390-2397.
|
| [19] |
Dong Y, Li Y, Xiang X, et al. Stress relief as a natural resilience mechanism against depression-like behaviors. Neuron. 2023; 111(23): 3789-3801.e6.
|
| [20] |
Nisson PL, Maeda T, Uchikawa H, Cisneros O, Lawton MT, Hashimoto T. Ventral midline hysterectomy, ovariectomy, and ovariohysterectomy in Mus musculus: a surgical protocol. Sci Rep. 2025; 15(1): 6625.
|
| [21] |
Alvord VM, Pendergast JS. The estrous cycle coordinates the circadian rhythm of eating behavior in mice. J Biol Rhythm. 2024; 39(5): 413-422.
|
| [22] |
Primo MJ, Fonseca-Rodrigues D, Almeida A, Teixeira PM, Pinto-Ribeiro F. Sucrose preference test: a systematic review of protocols for the assessment of anhedonia in rodents. Eur Neuropsychopharmacol. 2023; 77: 80-92.
|
| [23] |
Stukalin Y, Lan A, Einat H. Revisiting the validity of the mouse tail suspension test: systematic review and meta-analysis of the effects of prototypic antidepressants. Neurosci Biobehav Rev. 2020; 112: 39-47.
|
| [24] |
Knight P, Chellian R, Wilson R, Behnood-Rod A, Panunzio S, Bruijnzeel AW. Sex differences in the elevated plus-maze test and large open field test in adult Wistar rats. Pharmacol Biochem Behav. 2021; 204:173168.
|
| [25] |
Zhang K, Wang F, Zhai M, et al. Hyperactive neuronal autophagy depletes BDNF and impairs adult hippocampal neurogenesis in a corticosterone-induced mouse model of depression. Theranostics. 2023; 13(3): 1059-1075.
|
| [26] |
Mitre-Aguilar IB, Moreno-Mitre D, Melendez-Zajgla J, et al. The role of glucocorticoids in breast cancer therapy. Curr Oncol. 2022; 30(1): 298-314.
|
| [27] |
Ledesma-Corvi S, García-Fuster MJ. Aromatase inhibition and electroconvulsive seizures in adolescent rats: antidepressant and long-term cognitive sex differences. Int J Neuropsychopharmacol. 2023; 26(9): 607-615.
|
| [28] |
Kanwore K, Kanwore K, Guo X, et al. Testosterone upregulates glial cell line-derived neurotrophic factor (GDNF) and promotes neuroinflammation to enhance glioma cell survival and proliferation. Inflamm Regen. 2023; 43(1):49.
|
| [29] |
Pavlidi P, Kokras N, Dalla C. Antidepressants' effects on testosterone and estrogens: what do we know? Eur J Pharmacol. 2021; 899:173998.
|
| [30] |
Khatiz A, Tomlinson C, Ruzhytska B, et al. Real-time behavioral monitoring of C57BL/6J mice during reproductive cycle. Front Neurosci. 2025; 19:1509822.
|
| [31] |
Pourhamzeh M, Moravej FG, Arabi M, et al. The roles of serotonin in neuropsychiatric disorders. Cell Mol Neurobiol. 2022; 42(6): 1671-1692.
|
| [32] |
Shoji H, Maeda Y, Miyakawa T. Chronic corticosterone exposure causes anxiety- and depression-related behaviors with altered gut microbial and brain metabolomic profiles in adult male C57BL/6J mice. Mol Brain. 2024; 17(1):79.
|
| [33] |
Qin Z, Shi DD, Li W, et al. Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption. J Neuroinflammation. 2023; 20(1): 54.
|
| [34] |
Zhang Y, Tan X, Tang C. Estrogen-immuno-neuromodulation disorders in menopausal depression. J Neuroinflammation. 2024; 21(1):159.
|
| [35] |
Kietzman WB, Graham GT, Ory V, et al. Short- and long-term effects of CDK4/6 inhibition on early-stage breast cancer. Mol Cancer Ther. 2019; 18(12): 2220-2232.
|
| [36] |
Jin N, Qian YY, Jiao XF, et al. Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis. Redox Biol. 2025; 80:103528.
|
| [37] |
Hou B, Lee S, Lee JM, et al. Deep learning segmentation of ascites on abdominal CT scans for automatic volume quantification. Radiol Artif Intell. 2024; 6(5):e230601.
|
| [38] |
Wen W, Liang W, Wu J, et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther. 2014; 13(12): 3037-3048.
|
Rights & permissions
2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
PDF
(7196KB)
